Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. infliximab.
about
Predictive factors for a severe clinical course in ulcerative colitis: Results from population-based studiesTacrolimus for the Treatment of Ulcerative ColitisBiologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonistsUpdate on medical and surgical options for patients with acute severe ulcerative colitis: What is new?Outcomes of rescue therapy in acute severe ulcerative colitis: data from the United Kingdom inflammatory bowel disease audit.Tacrolimus or infliximab for severe ulcerative colitis: short-term and long-term data from a retrospective observational studyReview article: acute severe ulcerative colitis - evidence-based consensus statements.Review article: the practical management of acute severe ulcerative colitis.Infliximab versus Cyclosporine Treatment for Severe Corticosteroid-Refractory Ulcerative Colitis: A Korean, Retrospective, Single Center Study.Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trialCurrent and emerging maintenance therapies for ulcerative colitis.Ability of different rescue therapies to save the bowel in acute, severe, steroid-refractory ulcerative colitis.A Comparison of Short- and Long-Term Therapeutic Outcomes of Infliximab- versus Tacrolimus-Based Strategies for Steroid-Refractory Ulcerative Colitis.Early investigational TNF receptor antagonists for the treatment of ulcerative colitis.Cost-effectiveness of golimumab for the treatment of patients with moderate-to-severe ulcerative colitis in Quebec using a patient level state transition microsimulation.Cost-Utility Analysis of Infliximab with Standard Care versus Standard Care Alone for Induction and Maintenance Treatment of Patients with Ulcerative Colitis in Poland.Impact of Infliximab and Cyclosporine on the Risk of Colectomy in Hospitalized Patients with Ulcerative Colitis Complicated by Cytomegalovirus-A Multicenter Retrospective Study.Health care costs associated with Australian tertiary inflammatory bowel disease care.Tumor necrosis factor alpha blocking agents as treatment for ulcerative colitis intolerant or refractory to conventional medical therapy: a meta-analysisDoes the Cyclosporine Still Have a Potential Role in the Treatment of Acute Severe Steroid-Refractory Ulcerative Colitis?Letter: ciclosporin or infliximab in acute ulcerative colitis - still undecided; authors' reply.The effectiveness and safety of rescue treatments in 108 patients with steroid-refractory ulcerative colitis with sequential rescue therapies in a subgroup of patients.Commentary: salvage medical therapy for acute severe colitis - ciclosporin or infliximab?The incidence rate of colectomy for medically refractory ulcerative colitis has declined in parallel with increasing anti-TNF use: a time-trend study.The Human Gut Microbiome - A Potential Controller of Wellness and DiseasePrior response to infliximab and early serum drug concentrations predict effects of adalimumab in ulcerative colitisThe effect of pre-admission immunosuppression on colectomy rates in acute severe ulcerative colitis
P2860
Q26751156-9E4A5DFE-96A6-446D-92CC-A489746663F7Q26997361-C4F8403D-EF79-4D63-945B-5ADCA753F44FQ26999078-7B4EE11A-3E17-4FCC-9EB0-55AEA47EC502Q28073443-F6B21A79-44AC-4941-B8C1-045CFD0AC217Q30664895-20729495-F19E-40C0-A34A-8DE94E7BA9BFQ31004717-FC4C938B-F0C3-4330-B809-D9DDFDE84A74Q34528270-E5B417F7-4ACE-47EB-A550-80A94208B71FQ35883580-498BFFF7-57E9-4506-AF7E-24EF22B24099Q36037115-882EAF37-132D-4EAC-A34F-8A05808CF773Q37196938-88B37C84-E910-4303-A3EB-F6B1075A5A33Q38197719-87E244A0-D336-457F-B111-6C3D44EBDBF0Q38204993-BFB8D3AA-4E36-4FC8-9397-5A4395AF0942Q38287132-8E0789D0-054B-4863-B298-48FBA4C1022AQ38365426-7A52669F-2EBA-47B7-9F81-2D3101C3374DQ38613850-8F1BAFAE-BAD8-4E01-9F3D-AAB0DAE397C8Q39895230-73C1B970-C2A4-4C69-92C3-523DB79A3983Q40181878-ECD86D79-33D0-4208-9621-CFBAF2DA636AQ40199705-D05A073B-0FCB-42A5-8476-166C523680E2Q41894047-68C1D455-D3E0-4872-8ADB-816243C8D5FDQ43139980-54469DA0-6C14-4701-A11C-4CE03B9B3056Q43534755-C630A927-BBA9-4494-91A9-55F0A78C076BQ44033640-A9DDC347-0A1C-4DE9-8F5E-CC84ED933D13Q44641895-9CD56D13-5DDE-48BE-B1BA-A052D6D16E27Q51251490-533A09AA-9B5B-4E8F-ADCF-AB9F6EDAF761Q57169434-433E1598-AD55-4E8F-989B-4B33F807DD98Q57265310-B1881C87-E374-42C2-A0E3-89229745E7F1Q59129235-4EF489DC-3D8D-4F08-8156-6AA853B5A87C
P2860
Outcomes of salvage therapy for steroid-refractory acute severe ulcerative colitis: ciclosporin vs. infliximab.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Outcomes of salvage therapy fo ...... s: ciclosporin vs. infliximab.
@en
Outcomes of salvage therapy fo ...... s: ciclosporin vs. infliximab.
@nl
type
label
Outcomes of salvage therapy fo ...... s: ciclosporin vs. infliximab.
@en
Outcomes of salvage therapy fo ...... s: ciclosporin vs. infliximab.
@nl
prefLabel
Outcomes of salvage therapy fo ...... s: ciclosporin vs. infliximab.
@en
Outcomes of salvage therapy fo ...... s: ciclosporin vs. infliximab.
@nl
P2093
P2860
P356
P1476
Outcomes of salvage therapy fo ...... is: ciclosporin vs. infliximab
@en
P2093
P2860
P304
P356
10.1111/APT.12375
P407
P50
P577
2013-06-20T00:00:00Z